Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
Liver Disease	227.17M
Liver Disease Growth	-3.47%
Cardiovascular	196.87M
Cardiovascular Growth	18.85%
Antibacterial	119.02M
Antibacterial Growth	-21.56%
Gout	77.69M
Gout Growth	-15.76%
Technical Service Fee	37.76M
Technical Service Fee Growth	8.08%
Prostaglandins	22.08M
Prostaglandins Growth	-16.56%
Nervous System	12.21M
Nervous System Growth	-2.32%
Anti-tumor	11.62M
Anti-tumor Growth	582.50%
High-end Fluorine	3.07M
High-end Fluorine Growth	49.57%
Other	87.79M
Other Growth	-6.76%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
International	462.18M
International Growth	-7.24%
China	333.11M
China Growth	4.58%